Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer

Zhucheng Zhao1,2,5†, Yanmao Wang1,2†, Yuyan Gong1,2†, Xian Wang1,2, Luyao Zhang1,2, Haiyang Zhao4, Jifa Li3, Jiandong Zhu3, Xiaoying Huang1, Chengguang Zhao1,2, Lehe Yang1* and Liangxing Wang1*

Abstract

**Background:** Non-small cell lung cancer (NSCLC) is the most common lung cancer with high mortality across the world, but it is challenging to develop an effective therapy for NSCLC. Celastrol is a natural bioactive compound, which has been found to possess potential antitumor activity. However, the underlying molecular mechanisms of celastrol activity in NSCLC remain elusive.

**Methods:** Cellular function assays were performed to study the suppressive role of celastrol in human NSCLC cells (H460, PC-9, and H520) and human bronchial epithelial cells BEAS-2B. Cell apoptosis levels were analyzed by flow cytometry, Hoechst 33342, caspase-3 activity analysis, and western blot analysis. Intracellular reactive oxygen species (ROS) were analyzed by flow cytometry and fluorescence microscope. Expression levels of endoplasmic reticulum (ER) stress-related proteins and phosphorylated signal transducer and activator of transcription 3 (P-STAT3) were identified via western blot analysis. A heterograft model in nude mice was employed to evaluate the effect of celastrol in vivo.

**Results:** Celastrol suppressed the growth, proliferation, and metastasis of NSCLC cells. Celastrol significantly increased the level of intracellular ROS; thus, triggering the activation of the ER stress pathway and inhibition of the P-STAT3 pathway, and eventually leading to cell apoptosis, and the effects were reversed by the pre-treatment with N-Acetyl-l-cysteine (NAC). Celastrol also suppressed tumor growth in vivo.

**Conclusion:** The outcomes revealed that celastrol plays a potent suppressive role in NSCLC in vitro and in vivo. Celastrol induces apoptosis via causing mitochondrial ROS accumulation to suppress the STAT3 pathway. Celastrol may have potential application prospects in the therapy of NSCLC.

**Keywords:** Celastrol, STAT3, ROS, NSCLC, Inhibitor

---

**Background**

Lung cancer is one of the most common cancers in the world [1]. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and it includes lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and lung large cell cancer (LCLC) [2]. According to the latest annual report of global cancer statistics, NSCLC still occupies an important position in cancer-related deaths worldwide [3]. Although the progress in surgical treatment, systemic chemoradiotherapy, targeted...
therapy, and immunotherapy is gradually improving the clinical treatment effect in NSCLC patients, the prognosis is still not ideal [4, 5]. The five-year survival rate of patients with early NSCLC is still very low; only 15%, and the progression of cancer is almost inevitable. Currently, good treatment measures are not available for patients with advanced NSCLC [6, 7]. Therefore, it is very important to clarify the molecular mechanism of the occurrence and development of NSCLC, search for more specific and effective therapeutic targets, and develop new therapeutic drugs.

Reactive oxygen species (ROS) mainly include hydroxyl radical (OH–), superoxide anion radical (O₂–), and hydrogen peroxide (H₂O₂), which are the by-products in the process of the cellular aerobic metabolism [8]. Studies have shown that tumor cells have a higher basic level of ROS than normal cells due to their high metabolic status, mitochondrial dysfunction, and abnormal activation of oncogenes [9]. The antioxidant system in tumor cells can prevent the excessive accumulation of ROS and maintain the redox balance [10]. When the antioxidant system in cells is ineffective in removing excessive ROS, oxidative stress will increase and tumor cell apoptosis and autophagy will be induced. At this time, the toxic level of ROS will play an anti-tumor role [11]. High ROS levels in tumor cells also make them more vulnerable to cell damage caused by externally induced increases in ROS. In recent years, it has been confirmed that one of the mechanisms of the anti-tumor effects of some drugs, such as paclitaxel [12] and trienol [13], is to induce cells to produce toxic ROS. Therefore, therapy that amplifies ROS in tumor cells to toxic levels may be an effective anti-tumor approach.

Endoplasmic reticulum (ER) stress is a response process, in which cells respond to the accumulation of misfolded and unfolded proteins and calcium imbalance in the endoplasmic reticulum, and activate the unfolded protein response (UPR), ER overload response, and caspase-12 mediated apoptosis pathway [14]. ER stress occurs when ROS, hypoxia, or nutrient deficiency causes disruption of cellular redox regulation and imbalance of cellular homeostasis. In tumor cells, during the early stage of ER stress, the UPR can regulate protein folding and degrade unfolded proteins to maintain cell homeostasis [15]. When ER stress persists and the UPR cannot deal with unfolded proteins, ER stress can be mediated by the activating transcription factor 6 (ATF6), inositol requiring enzyme 1 (IRE1), and protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) signaling pathways that transduce downstream apoptotic pathways to induce apoptosis [16].

Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor. It plays an important role in cell functions, such as cell growth, survival, differentiation, metabolism, host defense, and immune regulation [17]. A large amount of research evidence has shown that abnormal activation of STAT3 occurs during the development, drug resistance, and metastasis of various human tumors, including NSCLC [18]. Inhibition of STAT3 activity has become an important way to prevent tumor occurrence and metastasis [19]. Relevant studies have reported that in prostate cancer [20] and gastric cancer [21], excessive accumulation of ROS can inhibit the STAT3 signaling pathway and exert an anti-tumor effect. Therefore, inhibition of the STAT3 signaling pathway by increasing ROS levels in tumor cells may be a new target for anti-tumor drugs.

Celastrol is the main bioactive ingredient extracted from traditional Chinese medicinal herb Tripterygium wilfordii [22]. Studies have shown that celastrol has potential cytotoxicity in a variety of tumor cells [21–23]. Recent studies have also found that celastrol can significantly increase the intracellular ROS levels, leading to apoptosis, cell cycle arrest, and autophagy of cancer cells [24, 25]. However, the antitumor mechanism of celastrol in NSCLC has not been fully understood. In this study, the effects of celastrol on proliferation, migration, invasion, and apoptosis of NSCLC cells were observed. The effects of celastrol on the ROS level, ER stress level, and STAT3 signaling pathway in NSCLC cells were observed. Finally, a xenograft tumor model of NSCLC in nude mice was constructed to observe the effect of celastrol on NSCLC in vivo; thus, providing a new research basis for celastrol as a potential drug for the treatment of NSCLC.

**Methods**

**Cell lines and cultivation**

H460, PC-9, H520 and BEAS-2B lineage cells were obtained from the Cellular Resources Center of the SIBS (CAS, PRC). PC-9 cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) (TFS). H460, H520 and BEAS-2B cells were cultivated in RPMI-1640 intermediary (TFS) with 10% FBS (TFS). The environment (5% CO₂, 37 °C) was provided for cell incubation.

**Antibodies and reagents**

Celastrol was supplied by Baoji Herbest Bio-Tech Co., Ltd. Media were provided by Invitrogen (America). Antisubstances of ATF4, phosphorylated eukaryotic initiation factor 2 alpha (P-EIF2α), EIF2α, STAT3, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were supplied by Cell Signaling Technology (USA). Antisubstances, P-STAT3 and BCL2 Associated X (BAX), were provided by Abcam Co. (USA). Antibodies of B-cell lymphoma-2 (BCL-2) and secondary antibodies were...
purchased from Santa Cruz Biotechnology Inc. (USA). The Overall Protein Abstraction Kit was supplied by Boster Biological Technology (PRC). Dimethylsulfoxide (DMSO) and methylthiazolyldiphenyltetrazolium bromide (MTT) were provided by Sigma-Aldrich Co. (USA). Apoptosis kits were purchased from BD Pharmin-gen (USA). The Caspase 3 Assay Kit was purchased from Abcam Co. (Cambridge, MA, USA). ROS probes 2′,7′-Dichlorodihydrofluorescin diacetate (DCFH-DA) and N-Acetyl-L-cysteine (NAC) were obtained from Bey-otime Biotech (Nantong, China).

**MTT cell toxicity assay**

Cell viability and cytotoxicity in mankind NSCLC cells were identified by MTT assay. Cells (4–5 × 10^5 per well) were seeded into plates with 96 wells. Then, different concentrations of celastrol were added into the plates for 48 h. Further, 25 µL MTT solution was added to the plates for 4 h before the MTT assay. Formazan crystals were dispersed in 150 µL DMSO and the optical density (OD) was identified via a Micro plate Reading device at 490 nm. The half-maximal inhibitory concentration (IC_{50}) data were identified via GraphPad Pro Prism 7.0.

**Colony formation analysis**

The colony formation activity was assessed by the colony forming analysis. Cells were implanted into 6-well plates in 5% CO_2 atmosphere at 37 °C overnight. Celastrol (1, 2, and 4 µM) and DMSO were supplemented into the plates for 24 h. Further, 7–14 days later, when colonies were macroscopic, the plate was cleaned with phosphate-buffered saline (PBS), treated with 4% paraformaldehyde (PFA) fixation under room temperature (RT) for 15 min, then cleaned with pure water 3 times and it was dyed with Gentian violet for 10 min.

**Wound-healing migration analysis**

Wound-healing analysis was employed to assess the capability of cell motility. The cells were grown to about 80–90% confluence in plates with 6 wells, and afterwards, scraping of the cell mono-layer was performed at the center of the wells with a bacteria-free 10 µL pipet to create a scratched region. After that, the plates were cleaned in PBS to remove the scratched cells. Subsequently, the cells were cultivated in RPMI intermediary (without sera) with vector control or celastrol (1, 2, and 4 µM). Leica digital camera (Tokyo, Japan) was employed for micro-photographs of cells that crossed the wound area.

**Transwell assay**

Transwell analysis was employed to assess the cellular invasion capability. The cells were seeded into a transwell chamber at 2–4 × 10^4 cells/chamber in conditioned medium overnight, and then they were treated with DMSO (Control) and celastrol (1, 2, and 4 µM) for 8 h. The upper intermediary was substituted by conditioned intermediary, and the lower intermediary was substituted by intermediary supplemented with 20% FBS. Afterwards, the cells were subjected to fixation in 4% PFA for fifteen min and dyed with Gentian violet for ten min. The invaded cells were photographed with a microscopy device.

**Measurement of ROS production in cells**

Cells were subjected to ROS-sensitive dye treatment, and the production of ROS within cells was detected via the flow cell technique. Briefly, three types of cells were placed into cultivation plates with 6 wells and cultivated overnight in standard cultivation intermediary. Afterwards, the cells were stimulated with celastrol at the indicated times and concentrations. The cells were dyed with 10 µM DCFH-DA under 37 °C for 0.5 h. The ROS status was identified via the flow cell technique (FACSCalibur, BD Biosciences, USA) and fluorescence images. In certain assays, the cells were subjected to 5 mM NAC pretreatment for 60 min. In the entire assays, 10,000 living cells were assayed.

**Cell apoptosis assay**

The Annexin V-FITC Programmed Cell Death Identification Kit I and Propidium Iodide (PI) were bought from BD Pharmingen (America). The human NSCLC cells were inoculated into dishes (each with 6 wells) for the purpose of growing the cells to 80% confluence in the maximum medium, and afterwards, the cells were subjected to different concentrations of celastrol (1, 2, and 4 µM) and DMSO (Control) treatment for 48 h to assess viability and cytotoxicity in mankind NSCLC cells.
Fig. 1 (See legend on previous page.)
Fig. 2  Celastrol induced apoptosis of human NSCLC Cells. A After treatment with celastrol at the indicated concentration for 24 h before staining with Annexin V and propidium iodide (PI), the distribution of apoptotic cells was determined using flow cytometry. B The apoptotic characteristics in NSCLC cell nucleus presented by Hoechst Staining assay. After treatment with celastrol for 12 h before staining with Hoechst staining, the nucleus was observed and photographed (100×). Representative results of triple experiments. C Caspase 3 activity was evaluated using the Caspase Assay Kit, and absorbance was recorded at 405 nm. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)
the roles of celastrol in programmed cell death. In certain assays, the cells were subjected to 5 mM NAC pretreatment for 60 min. The cells were harvested and cleaned with cold PBS for 2 times, and afterwards, they were subjected to resuspension in binding buffering solution as per the specification of the Programmed Cell Death Kit. The cells were synchronously cultured with luciferin-labeled Annexin V and PI. Afterwards, the Annexin V-binding buffering solution was added into the mix and the fluorescence property was identified on a FACS Calibur (USA). The Flowjo program was employed to analyze the figures.

Hoechst 33342 staining
NSCLC cells were seeded in a six-well culture plate. After treatment with celastrol for 12 h, 4% PFA was used for 10 min for cell fixing, and the cells were cleaned in PBS, followed by Hoechst 33342 dyeing for 20 min. The characteristic of cell nucleus was observed by employing a fluorescence microscope (Leica, Tokyo, Japan).

Determination of caspase 3 activity
Cells (1 x 10^6 to 5 x 10^6) were spread in petri dishes. Celastrol (1, 2, and 4 μM) was added to induce apoptosis in NSCLC cells. The cells were resuspended and lysed in 50 μL pre-treated lysis buffering solution for ten min on ice and then centrifuged for 1 min. The supernatant fraction was immediately transferred into a fresh tube. The reaction system was subsequently configured as specified in the Caspase 3 binding assay kit and maintained under 37 °C for 120 min. The absorbance was identified under 405 nm via a SpectraMax iD3 (USA).

Western blot analysis
Tissue or cellular protein lysate buffering solution was utilized to perform protein extraction. Three cancer cell lines were seeded in the six plates, treated with celastrol for 3 h, and then dissolved with a cold lytic buffer. The 10% or 12% SDS-PAGE was used for protein separation. Proteins were translocated onto a PVDF film, followed by incubation for 1.5 h with 5% skimmed milk. The film was cultivated under 4 °C with specific antisubstances. Afterwards, the membrane underwent 1 h incubation at room temperature with the corresponding secondary antibody. Image J computer software was used for determining the density of the immune response bands.

Cytoplasmic and nuclear protein extraction
We employed the NE-PER Nuclear and Cytoplasmic Extraction Kit to isolate the nucleus and cytoplasmic proteins in H460 cells (TFS). Cells were subjected to treatment with diverse concentrations of celastrol for 12 h, and afterwards, they were stimulated with IL-6 for 0.5 h. According to the protocol, the cell lysate was obtained. Immunoblotting assy was performed to identify the related protein expression.

Immunofluorescence staining
H460 cells were inoculated into a fluorescence cuvette, and they were treated with celastrol and/or IL-6. Then, the cells were subjected to 4% PFA fixation and permeabilization via 0.5% Triton X-100 (in PBS), and cleaned three times with PBS. Afterwards, they were subjected to 1% BSA blockade for 60 min. Cell slides were cultivated with the first antisubstance (P-STAT3) in appropriate proportions. The cells were cultivated with an anti-rabbit secondary antisubstance (Alexa Fluor® 488) on the following day and then with the DAPI stain protected from light. The cell slides were cleaned in PBS again and subsequently sealed by anti-fluorescence quenching sealing tablets to prevent fluorescence quenching until they were captured by confocal microscopy (Nikon C2).

Animal model
The WMU Animal Policy and Welfare Board accepted the entire murine assays. Athymic BALB/c nude mice (16–18 g) were bought from the Vital River Experimental Animal Center (PRC). For the heterograft model, H460 cells (5 x 10^6 cells) blended with the same volume of PBS and Matrigel in 100 μL were delivered into the hind flank of the animals. If tumor volumes were ~ 50 mm^3, the animals were separated into 4 experiment groups and they were injected with 4 mg/kg napabucasin (a recognized P-STAT3 suppressor) or celastrol (2 and 4 mg/kg)
Fig. 3 (See legend on previous page.)
intraperitoneally every other day. Tumor volume was calculated as \( V = (L \times W \times W)/2 \), where \( L \) and \( W \) denote the length and width, respectively. The mice were euthanized on day 15, 2 h after the final drug administration. The tumors, hearts, livers, kidneys, and lungs were collected for the histological and immunoblotting assays.

**Immunohistochemical staining**

Tumor samples were subjected to fixation under RT with 4% PFA and embedded with paraffin. The thickness of the treated tissues slices was 5 µm. After that, the samples were cultivated overnight with the proper primary antisuface under 4 °C. The signal was identified via the relevant second antisuface. Subsequently, these sections were dyed with DAB and counterstained with hematoxylin. Imaging was performed via optical microscopy.

**Hematoxylin and eosin (H&E) staining**

The hearts, lungs, kidneys, and livers of mice were treated with 4% PFA fixation and paraffin embedment. The treated tumor sample slices (5 µM) were deparaffinized and subjected to rehydration, and afterwards, they were treated with H&E dyeing. Imaging was performed via optical microscopy.

**Statistical analysis**

Data were presented as average \( \pm \) SEM of three independently performed assays. The diversity in statistics between diverse groups was analyzed via the Student’s t-test in GraphPad Pro7.0 (USA). \( P < 0.05 \) was deemed statistically significant.

**Results**

**Celastrol suppressed the viability, migration, and invasion of NSCLC cells**

The chemical structure of celastrol is shown in Fig. 1A. For the purpose of evaluating the suppressive role of celastrol, cellular activity was evaluated via the MTT analysis. Celastrol significantly inhibited the activity of H460, PC-9, and H520 cells, with IC\(_{50}\) values of 1.288 µM, 2.486 µM, and 1.225 µM, respectively (Fig. 1B). The cell counting trypan blue assay showed that the growth of H460 and PC-9 cells was significantly inhibited by celastrol in a concentration dependent manner (Additional file 1: Fig. S1A). Besides, the colony forming analysis revealed that celastrol could markedly inhibit the colony forming capability of NSCLC cells (Fig. 1C). Additionally, for the purpose of determining whether the treatment with celastrol was related to oncocyte migration and invasion, variations in migratory and invasive potency were identified via the wound healing assay and transwell assay; in contrast to controls, the migratory and invasive potency of these three lineage cells was dose-dependently inhibited by celastrol (Fig. 1D and E, and Additional file 1: Fig. S1B). At the same time, we conducted the same experiment in normal human cells. The results showed that celastrol had no obvious inhibitory effect on cell viability. To sum up, these results revealed that celastrol could validly suppress the viability, migration, and invasion of mankind NSCLC cells.

**Celastrol induced apoptosis of human NSCLC cells**

To assess whether celastrol can trigger programmed cell death, 3 lineage cells, H460, PC-9, and H520 were subjected to celastrol treatment at 3 diverse concentrations for 24 h, followed by staining with Annexin V FITC and PI, and the proportion of programmed cell death was identified via the flow cell technique. Celastrol markedly triggered programmed cell death in NSCLC cells (Fig. 2A). The outcomes of Hoechst 33342 dyeing showed that the celastrol-treated cells showed a potent blue fluorescent result and obvious apoptosis bodies. It was further confirmed that celastrol could induce apoptosis (Fig. 2B). Here, we also found that the activity of caspase 3 was significantly increased, as determined by the caspase activity assay, and the pro-apoptotic effect of celastrol was confirmed (Fig. 2C). Overall, celastrol markedly promoted apoptosis of NSCLC cells.

**Celastrol induced oxidative stress in human NSCLC cells**

The production of ROS will cause programmed apoptosis. Promoting apoptosis by increasing ROS in tumor cells is one of the mechanisms of action of many chemotherapeutic agents [26, 27]. For the purpose of clarifying whether celastrol-triggered programmed cell death occurred due to ROS generation, we exposed H460, PC-9, and H520 cells to 4 µM celastrol and identified ROS via DCFH-DA dyeing. The numerical results herein revealed that celastrol remarkably elevated the ROS levels in NSCLC cell lines in a time-dependent manner (Fig. 3A, B and Additional file 2: Fig. S2A, B). Celastrol (See figure on next page.)

**Fig. 4** Celastrol activated ER stress through ROS. A Celastrol rapidly activates the ER stress pathway. H460, PC-9, and H520 cells were exposed to 4 µM celastrol for indicated times. Lysates were detected for p-eIF2α and ATF4. eIF2α and GAPDH was used as controls. B Effect of NAC on celastrol-induced ER stress. H460, PC-9, and H520 cells were pretreated with 5 mM NAC for 1 h and exposed to celastrol for 3 h. Western blot detected the lysates. Outcomes are representative of three independent experiments (\( *P < 0.05 \), \( **P < 0.01 \), \( ***P < 0.001 \), \( ****P < 0.0001 \))
Fig. 4  (See legend on previous page.)
displayed dosage-reliant triggering of ROS in H460, PC-9, and H520 cells. As anticipated, the ROS signal was decreased in cells subjected to oxidation preventive NAC pretreatment (Fig. 3C, D and Additional file 2: Fig. S2C, D). ROS fluorescence images also showed that the intracellular green fluorescence increased rapidly with the time period of celastrol treatment (Fig. 3E and Additional file 2: Fig. S2E, F). Similarly, the intracellular green fluorescence accumulated with increasing drug concentration, and pretreatment with NAC could eliminate this phenomenon (Fig. 3F and Additional file 2: Fig. S2G, H).

Afterwards, NAC was utilized to identify the participation of ROS in celastrol-triggered programmed cell death in NSCLC cells. Flow cytometry revealed that celastrol-triggered programmed cell death in H460 and PC-9, and H520 cells was reversed by 5 mM NAC pretreatment (Fig. 3G). These results were confirmed by the levels of apoptosis proteins, BAX and BCL-2 (Fig. 3H). Overall, the results indicated that an enhanced ROS level is the critical modulator of celastrol-triggered programmed cell death in NSCLC cells.

**Celastrol stimulated ER stress through ROS**

Increased ROS levels have been found to trigger programmed cell death via various downstream pathways, such as ER stress and mitochondrion-related functional disorder [28]. Therefore, our team examined ER stress-related proteins, such as ATF4, P-eIF2α, and eIF2α, to determine if ROS levels elevated via celastrol triggered ER stress in NSCLC cells. These biomarkers of ER stress were rapidly increased in H460, PC-9, and H520 cells exposed to celastrol and this triggering occurred as early as 1 h after the treatment (Fig. 4A). Celastrol also dosage-dependently stimulated the production of ER stress-associated proteins, and after NAC pretreatment of NSCLC cells for 1 h, this induction was prevented (Fig. 4B). These research findings provide conclusive evidence that celastrol triggers ROS; thus, inducing ER stress and causing programmed cell death in NSCLC cells.

**Celastrol inhibited the IL-6/STAT3 signaling pathway in NSCLC cells**

Previous studies have reported that ROS regulate a variety of cell signal paths, and elevated ROS levels can inhibit the STAT3 pathway [21]. As a transcriptional factor, STAT3 is pivotal for oncocyte growth and development [29]. For this reason, our team reckoned whether celastrol could influence the IL-6/STAT3 signaling pathway in NSCLC cells. Cytokine IL-6 is the main inflammatory mediator and stimulator of STAT3, which can block programmed cell death and facilitate cancer survival. Therefore, our team used 20 ng/ml IL-6 and different concentrations of celastrol to treat H460, PC-9, and H520 cells. The result showed that the stimulation of STAT3 triggered by IL-6 was dosage-dependently reversed by celastrol (Fig. 5A). In addition, as per the immunofluorescence dyeing analysis, IL-6 therapy induced the cytoplasm-nucleus P-STAT3 transfer, which could be inhibited by celastrol (Fig. 5B). We used western blotting to detect the protein expression in the cytoplasm and nuclear extracts. These results further confirmed that the nuclear translocation of P-STAT3 was significantly inhibited by celastrol (Fig. 5C). We found that P-STAT3 in H460, PC-9, and H520 cells was markedly reduced with celastrol treatment; however, under the same treatment conditions, the expression of STAT3 did not change significantly. Interestingly, the inhibitory effect of celastrol-induced P-STAT3 was reversed after NAC pretreatment for 1 h in the three cell lines (Fig. 5D). Finally, we investigated the expression of ER stress related proteins after IL-6 and celastrol co-treatment, The experimental results are shown in the Additional file 2: Fig. S2I. The level of ER stress in IL-6 and celastrol co-treated group was higher than that in IL-6 treated group, but lower than that in celastrol treatment group, this suggests that IL-6 stimulated STAT3 phosphorylation can reduce the ER stress level caused by celastrol. This suggests that celastrol inhibits the STAT3 pathway by accumulating intracellular ROS. To sum up, these outcomes revealed that celastrol suppressed the IL-6/STAT3 pathway via ROS production in NSCLC cells.

**The therapeutic action of celastrol in vivo**

To further evaluate the anti-cancer efficiency of celastrol in vivo, we established and employed the cell-derived xenograft NSCLC model, and the H460 NSCLC cell line was selected for model establishment. The STAT3 suppressor napabucasin was utilized as the positive control. The mean volumes of tumors in the celastrol group (2 mg/kg or 4 mg/kg) were smaller compared to those in the control group and napabucasin (4 mg/kg) group.
Fig. 5 (See legend on previous page.)
Fig. 6 The therapeutic action of celastrol in vivo. A Tumor volumes. B Representative figures of the tumor tissue in the celastrol-administered and control groups (n = 7). C Measurement of tumor weights. D Body weight of mice. E Hematoxylin and eosin staining of hearts, livers, lungs, and kidneys from nude mice at 200× magnification. F The expression of P-STAT3 and P-eIF2α was detected by IHC in tumor tissues. G Representative blots indicating the expressions of P-STAT3, ATF4, P-eIF2α, BAX, BCL-2, STAT3, eIF2α, and GAPDH in tumor tissues. The images shown are representative of three separate experiments (**P < 0.01, ***P < 0.001, ****P < 0.0001)
(Fig. 6A), and the image of the tumors excised from nude mice after seven sessions of treatment with celastrol or napabucasin showed similar results (Fig. 6B). Consistent with the above data, the results shown in Fig. 6C indicated great reduction in the tumor weight after treatment with celastrol. Importantly, the body weight of mice did not decrease obviously (Fig. 6D), and the image of HE staining of vital organs (Heart, liver, kidney, and lung) did not present apparent toxicities (Fig. 6E). Thus, celastrol showed relative safety in vivo. As presented in Fig. 6F, the immunohistochemical results of NSCLC cells showed that, after injection of celastrol, the expression of P-STAT3 was decreased as the P-eif2α proteins increased (Fig. 6F). Western blotting showed that treatment with celastrol decreased the level of P-STAT3 and triggered the expression of apoptotic protein BAX; the BCL-2 level was inhibited. Meanwhile, ER stress induced by celastrol in the in vivo NSCLC model was also verified; the levels of ATF4 and P-eIF2α proteins were increased (Fig. 6G). Altogether, these results suggested that celastrol suppresses cancer development and cellular proliferative activity in vivo.

**Discussion**

With an in-depth understanding of the molecular mechanisms of tumor genesis and development, it has become an important to discover active ingredients from natural products for the treatment of malignant tumors and clarify their mechanism of action [30–32]. In fact, several traditional chemotherapy drugs, including paclitaxel, epothilone, and vinca alkaloids, are derived from natural plants [32]. Celastrol is a triterpenoid compound extracted from Tripterygium wilfordii, a traditional Chinese medicinal herb. Celastrol has multiple biological pharmacological activities, which can not only inhibit inflammation and immune response, but can also enhance the sensitivity of the brain to leptin and inhibit hunger and obesity. In recent years, its anti-tumor activity has been reported [22, 33, 34]. Previous studies have found that celastrol has an inhibitory effect on a variety of NSCLC cell lines, but the specific mechanism of its anti-NSCLC effect is not clear [22, 35–37]. In this study, we found that celastrol could significantly inhibit the proliferation, clonogenesis, migration, and invasion of NSCLC cells, and cause excessive ER stress activation by

![Fig. 7 Mechanism of celastrol against NSCLC](image-url)
significantly increasing the intracellular ROS level; thus, leading to the occurrence of apoptosis, while the ROS inhibitor NAC could completely reverse this effect. Further studies showed that celastrol could inhibit the STAT3 signaling pathway, and NAC could reverse the inhibitory effect of celastrol on the STAT3 signaling pathway. These results suggest that ROS may play a key role in the anti-NSCLC effect of celastrol (Fig. 7).

In this study, it was found that celastrol could induce apoptosis of NSCLC cells by flow cytometry and caspase-3 enzyme activity assay. Therefore, in order to determine whether celastrol-induced apoptosis is mediated by ROS, the DCFH-DA probe was used to label celastrol-treated cells. Intracellular ROS levels were detected by fluorescence microscopy and flow cytometry. The results showed that celastrol significantly increased the intracellular ROS levels in a time- and concentration-dependent manner. The apoptosis rate of NSCLC cells induced by celastrol was significantly reduced after the cells were pretreated with the antioxidant NAC. Western blot also showed that BAX protein expression was increased and BCL-2 protein expression was decreased in NSCLC cells treated with celastrol. NAC reversed this effect. These results suggest that celastrol induces apoptosis of human NSCLC cells through ROS-mediated oxidative stress injury.

The expression of ER stress-related proteins, P-eIF2α and ATF4, was significantly up-regulated in Western blot, indicating that celastrol induced ER stress in NSCLC cells. Previous studies have found that celastrol can induce a large amount of ROS production in NSCLC cells. In order to determine whether ROS levels of NSCLC cells is induced by ROS, we added the antioxidant NAC to pretreat the cells. Western blot results showed that NAC significantly reduced the upregulation of ER stress-related proteins induced by celastrol. These results indicate that ROS may be the initiating factor of ER stress, and continuous and intense ER stress induces apoptosis of NSCLC cells.

Our study also showed that celastrol significantly inhibited STAT3 expression in a dose-dependent manner, even when stimulated by IL-6, the STAT3 activator. Previous studies have found that excessive accumulation of ROS in tumor cells can inhibit the STAT3 signaling pathway [20, 21]. Our study found that celastrol could significantly increase the ROS level in NSCLC cells and inhibit the STAT3 signaling pathway. In order to determine whether celastrol inhibits the STAT3 signaling pathway in NSCLC cells by ROS mediation, we tested STAT3 phosphorylation levels under different treatment conditions by Western blot, and the results showed that the antioxidant NAC could reverse the inhibitory effect of celastrol on the STAT3 signaling pathway. These results indicate that excessive accumulation of ROS induced by celastrol inhibits the STAT3 signaling pathway in NSCLC cells.

This study also evaluated the antitumor effect of celastrol in vivo, and found that celastrol reduced the volume and weight of NSCLC tumors. Celastrol inhibited the expression of P-STAT3 and promoted the expression of ATF4 and P-eIF2α. Celastrol up-regulated the expression level of BAX and down-regulated the expression level of BCL-2, which were consistent with the results of in vitro cell studies.

Conclusion
In conclusion, our study indicates that celastrol has a significant inhibitory effect on NSCLC in vivo and in vitro, and ROS may be the key factor for celastrol to exert an anti-NSCLC effect. Celastrol can significantly increase the ROS levels in NSCLC cells, and then trigger ER stress and induce cell apoptosis. At the same time, high intracellular ROS level can also exert an anti-NSCLC effect by inhibiting the STAT3 signaling pathway. Celastrol has potential application prospects in drug therapy of NSCLC.

Acknowledgements
Not applicable.

Author contributions
LXW, CGZ and LHY designed the research and got the funding. ZCZ performed the experiment and data analysis and drafted the manuscript. YMW, JFL and XW carried out the experiment, data collection and interpretation. YYG, JDZ and LYZ were responsible for methodology and software. LHY and XYH revised the manuscript. All authors agree to be accountable for
all aspects of work ensuring integrity and accuracy. All authors read and approved the final manuscript.

Funding
This work was financially supported by the National Natural Science Foundation of China (82203322 and 82173856), Natural Science Foundation of Zhejiang Province (LY21H030005 and LY20H030001), Wenzhou Municipal Science and Technology Bureau (Y20200225 and H20210009) and Medical Scientific Research Fund of Zhejiang Province (2020KY298).

Availability of data and materials
The data set used and analyzed in this article would be available from the corresponding author on request.

Declarations

Ethics approval and consent to participate
All experimental rats were handled humanely, and all procedures were strictly performed according to the guided and approved by the Animal Policy and Welfare Committee of Wenzhou Medical University.

Consent for publication
All authors have agreed to publish this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1. The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China. 2. School of Pharmaceutical Sciences, Wenzhou Medical University, Building 11, Chashan Street, University Town, Wenzhou 325035, Zhejiang, China. 3. Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou 325600, Zhejiang, China. 4. The Institute of Life Sciences, Wenzhou University, Wenzhou 325035, Zhejiang, China. 5. Department of Oncology, Jianyi People’s Hospital, Jingzhou 433300, Hubei, China.

Received: 14 August 2022   Accepted: 30 October 2022
Published online: 12 November 2022

References

1. Cao MM, Li H, Sun DQ, Chen WQ. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun. 2020;40:205–10.
2. Li BQ, You J, Huant T, Cai YD. Classification of non-small cell lung cancer based on copy number alterations. PLoS ONE. 2014;9:8.
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. 2022. CA Cancer J Clin. 2022;72:7–33.
4. Wakelee H, Kelly K, Edelman MJ. 50 years of progress in the systemic therapy of non-small cell lung cancer. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2014. p. 177–189.
5. Doroshov DB, Samarmad MF, Hastings K, Politi K, Rimm DL, Chen LP, Melero I, Schalper KA, Herbst RS. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25:492–602.
6. Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol. 2013;10:334–43.
7. Cortes-Denicks L, Galetta D. The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges. Cell Oncol. 2020;43:513–513.
8. Yuan DT, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelmann M, Connor TO, Stadler M, Meister M, et al. Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell. 2017;31:771–89.
9. Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liaison in cancer cells. Cell Death Dis. 2016;7:12.
10. Gonnin C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931–47.
11. Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64.
12. Alexandre J, Hu YM, Lu WQ, Pellicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Carn Res. 2007;67:3512–7.
13. Jeanne M, Lallemant-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Sollihi H, Raught B, de The H. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18:88–98.
14. Kim I, Xu WJ, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008;7:1013–30.
15. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14:581–97.
16. Urra H, Dufey E, Lisbona F, Rojas-Rivera D, Hetz C. When ER stress reaches a dead end. BBA-Mol Cell Res. 2013;1833:3507–17.
17. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signaling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–46.
18. Wu K, Chang QS, Yu L, Qi P, Chen BL, Thakur C, Sun JY, Li LZ, Kowluru A, Chen F. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget. 2013;4:2430–8.
19. Yang LH, Zhou F, Zhuang Y, Liu YA, Xu LY, Zhao HY, Xiang YQ, Dai XX, Liu ZG, Huang XY, et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CKD9/STAT3 signalling pathway. Br J Cancer. 2021;24:645–57.
20. Chen W, Li P, Liu Y, Yang Y, Ye XT, Zhang FY, Huang H. Isolantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells. J Exp Clin Cancer Res. 2018;37:12.
21. Cao Y, Wang J, Tian H, Fu GH. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of PI3K<sup>++</sup>-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res. 2020;39:15.
22. Kanaan R, Manu KA, Chen LX, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP, Sethi G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3K/Akt signaling pathways. Apoptosis. 2011;16:1028–41.
23. Yan F, Wu ZH, Li ZH, Liu L. Celastrol inhibits migration and invasion of triple-negative breast cancer cells by suppressing interleukin-6 via down-regulating nuclear factor-kappa (NF-kappa B). Med Sci Monit. 2020;26:9.
24. Chen X, Zhao Y, Luo W, Chen SA, Lin F, Zhang X, Fan SJ, Shen X, Wang Y, Liang G. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics. 2020;10:3290–308.
25. Liu X, Hu X, Wang XJ, Wang L, Zhu YJ, Song YD. Gao W. Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res. 2019;38:184.
26. Mi YS, Xiao CX, Du QW, Wu WQ, Qi GY, Liu XB. Molordin IC couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways. Free Radical Biol Med. 2016;90:230–42.
27. Chen WQ, Zhou P, Zhao ZW, Chen X, Fan XX, Vinothkumar R, Cui R, Wu FZ, Zhang QQ, Liang G, Ji JS. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer. Redox Biol. 2021;10:78.
28. Plackova P, Sala M, Smidkova M, Mejtek M, Hrebacek H, Nencra K, Thibaut HJ, Neyts J, Mertikova-Kasirova H. 9-Norbormyl-6-chloropurine (NCP) induces cell death through GSH depletion-associated ER stress and mitochondrial dysfunction. Free Radical Biol Med. 2016;97:223–35.
29. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 2008;19:341–50.
30. Kim C, Kim B. Anti-cancer natural products and their bioactive compounds inducing ER stress-mediated apoptosis: a review. Nutrients. 2018;10:29.
31. Bishayee A, Sethi G. Bioactive natural products in cancer prevention and therapy: progress and promise. Semin Cancer Biol. 2016;40:41–13.
32. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002;2:143–8.
33. Venkatesha SH, Dudicis S, Astby B, Moudgil KD. Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathog Dis. 2016;74:12.
34. Xu SH, Feng YQ, He WS, Xu W, Xu W, Yang HJ, Li XY. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res. 2021;167:11.
35. Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L, Leung ELH. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. Molecules. 2014;19:3508–22.

36. Lee YJ, Kim SY, Lee C. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non-small cell lung cancer cells. Mol Med Rep. 2019;19:3230–6.

37. Mou HB, Zheng Y, Zhao P, Bao HY, Fang WJ, Xu N. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicol In Vitro. 2011;25:1027–32.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.